Kaisa Huhtinen

Turku, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

CA-125 glycovariant assays enhance diagnostic sensitivity in the detection of epithelial ovarian cancer.

CA-125 glycovariant assays enhance diagnostic sensitivity in the detection of epithelial ovarian cancer.

Journal: Clinical chemistry and laboratory medicine
Published: May 09, 2025

Novel glycovariant biomarkers of CA125 and CA15-3 and their diagnostic performance across histotypes of ovarian cancer: A multi-cohort study in Sweden and Finland.

Novel glycovariant biomarkers of CA125 and CA15-3 and their diagnostic performance across histotypes of ovarian cancer: A multi-cohort study in Sweden and Finland.

Journal: European journal of obstetrics, gynecology, and reproductive biology
Published: March 19, 2025

Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer.

Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer.

Journal: Cancer research
Published: November 25, 2024

MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.

MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer.

Journal: Scientific reports
Published: August 09, 2024

Deciphering cancer genomes with GenomeSpy: a grammar-based visualization toolkit.

Deciphering cancer genomes with GenomeSpy: a grammar-based visualization toolkit.

Journal: GigaScience
Published: January 09, 2024

Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.

Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.

Journal: BMC cancer
Published: October 25, 2023

HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.

HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.

Journal: Gynecologic oncology
Published: August 13, 2023

Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis.

Quantification of cell death and proliferation of patient-derived ovarian cancer organoids through 3D imaging and image analysis.

Journal: STAR protocols
Published: July 28, 2023

Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.

Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 25, 2023

PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.

PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.

Journal: Neoplasia (New York, N.Y.)
Published: July 18, 2023

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.

Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence.

Journal: Translational oncology
Published: July 17, 2023

Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level.

Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level.

Journal: Scientific reports
Published: July 02, 2023
Showing 1-12 of 54

Last Updated: 09/26/2026